Altermune Technologies LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Altermune Technologies LLC
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research, Analytical Equipment and Supplies sectors. This month’s column covers deals announced December 2015 through January 2016.
Following the dissolution of its partnership with Sanofi, MannKind's next gambit is licensing its dry-powder delivery technology to new company Receptor Life Sciences. We also highlight our sister publication IN VIVO's deal of the year winners in the alliance, M&A and financing categories.
Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.
In Vivo briefly describes these recently founded companies: Altermune Technologies, Ariel Pharmaceuticals, AUM Cardiovascular, BioMoti, Tensha Therapeutics and Trevi Therapeutics.
- Antisense, Oligonucleotides
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.